GYRE THERAPEUTICS, INC.
No SEC Form 4 filings for $GYRE in the last 30 days.
GYRE THERAPEUTICS, INC. (GYRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gyre-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 milli
Gyre Therapeutics (Nasdaq: GYRE) reported Q2 2026 revenue of $29.1 million and GAAP basic EPS of $(0.12). Full-year 2026 revenue guidance of $100.5 to $111.0 million was affirmed. The company said China’s CDE accepted its F351 NDA for CHB-induced liver fibrosis in May 2026 and noted Q2 sales growth for ETUARY.
GYRE THERAPEUTICS, INC. (GYRE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2026 Gyre Therapeutics, Inc . (Exact name of registran
Over the past 7 days, alphai's AI scored 2 news stories mentioning GYRE (GYRE THERAPEUTICS, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent GYRE coverage spans insider activity, financial news and earnings.
Near-term trading focus is on affirmed revenue guidance plus regulatory progress in China (NMPA NDA acceptance) and ongoing commercialization/product sales trends.
Near-term catalyst is regulatory progress on F351 plus affirmed full-year revenue guidance, with additional upside optionality from Cullgen’s degrader pipeline.
Board refresh and committee appointments are unlikely to change near-term fundamentals, but can modestly affect governance expectations and sentiment.
Shareholder votes were completed: directors elected, executive comp approved (non-binding), auditor ratified, and Series B preferred conversion approved.
Routine insider selling via open-market transactions; may slightly pressure sentiment but lacks evidence of fundamental deterioration in the filing itself.
alphai scores every news story that mentions GYRE with an AI model for sentiment and relevance, and aggregates insider trades from GYRE THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GYRE THERAPEUTICS, INC. (GYRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gyre-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 milli
6 min readGyre Therapeutics (Nasdaq: GYRE) reported Q2 2026 revenue of $29.1 million and GAAP basic EPS of $(0.12). Full-year 2026 revenue guidance of $100.5 to $111.0 million was affirmed. The company said China’s CDE accepted its F351 NDA for CHB-induced liver fibrosis in May 2026 and noted Q2 sales growth for ETUARY.
7 min readGYRE THERAPEUTICS, INC. (GYRE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2026 Gyre Therapeutics, Inc . (Exact name of registran
2 min readGYRE THERAPEUTICS, INC. (GYRE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001124105 NASDAQ 0001124105 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1
2 min readYe Weiguo (Chief Operating Officer) sold 20,918 shares of GYRE THERAPEUTICS, INC. (GYRE) at an average of $6.16 ($6.14–$6.21, $0.13M total) across 2 trades over 2026-06-09 to 2026-06-10.
1 min readYe Weiguo (Chief Operating Officer) sold 34,976 shares of GYRE THERAPEUTICS, INC. (GYRE) at an average of $6.25 ($6.13–$6.40, $0.22M total) across 2 trades over 2026-06-04 to 2026-06-05.
1 min readYe Weiguo (Chief Operating Officer) sold 3,500 shares of GYRE THERAPEUTICS, INC. (GYRE) at $6.08 on 2026-05-22.
2 min readGyre Therapeutics' EVP and General Manager, Jialiang Wang, has reported initial holdings of multiple stock options for the company's common stock, as detailed in a recent Form 3 filing. The filing outlines various grants with different exercise prices and expiration dates, indicating a structured long-term equity incentive for Wang. Some options are fully vested, while others vest over time, contingent on continued service to the company.
2 min readGyre Therapeutics' Chief Scientific Officer, Xiong Yue, has reported his initial ownership of 2,376,500 shares of Series B Preferred Stock following the merger of a Gyre subsidiary with Cullgen Inc. These shares are convertible into common stock at a 5:1 ratio after stockholder approval and are subject to a beneficial ownership limitation. The merger, effective May 4, 2026, resulted in Cullgen becoming a wholly-owned subsidiary of Gyre Therapeutics.
3 min readGyre Therapeutics (GYRE) General Counsel and Corporate Secretary, Joshua Benjamin Bergmann, has reported his initial ownership of a stock option for 47,530 shares of common stock. The option has an exercise price of $8.09 per share and expires on February 27, 2036. Vesting will occur in stages, with one-quarter on June 16, 2026, and the remainder monthly over the following three years, contingent on his continued employment.
2 min read